Eyenovia (NASDAQ:EYEN) Issues Quarterly Earnings Results, Hits Expectations

Eyenovia (NASDAQ:EYEN) released its earnings results on Monday. The company reported ($0.17) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.17), Yahoo Finance reports. During the same period in the prior year, the company earned ($0.17) EPS.

Eyenovia Price Performance

Shares of Eyenovia stock traded up $0.10 during trading on Wednesday, reaching $1.28. 623,627 shares of the company’s stock were exchanged, compared to its average volume of 825,260. The company has a debt-to-equity ratio of 0.70, a quick ratio of 4.04 and a current ratio of 4.05. Eyenovia has a 1-year low of $1.05 and a 1-year high of $5.85. The company has a market cap of $56.25 million, a P/E ratio of -1.75 and a beta of 1.72. The firm’s 50-day moving average price is $1.76 and its 200 day moving average price is $1.64.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Eyenovia in a research report on Tuesday.

Institutional Trading of Eyenovia

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its position in Eyenovia by 4.5% in the fourth quarter. Vanguard Group Inc. now owns 1,429,577 shares of the company’s stock valued at $2,974,000 after purchasing an additional 61,732 shares during the last quarter. BlackRock Inc. raised its position in shares of Eyenovia by 1,704.3% during the second quarter. BlackRock Inc. now owns 1,334,953 shares of the company’s stock worth $3,164,000 after acquiring an additional 1,260,966 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Eyenovia by 113.6% during the second quarter. Geode Capital Management LLC now owns 555,479 shares of the company’s stock worth $1,316,000 after acquiring an additional 295,412 shares during the last quarter. State Street Corp raised its position in shares of Eyenovia by 433.5% during the second quarter. State Street Corp now owns 442,382 shares of the company’s stock worth $1,048,000 after acquiring an additional 359,465 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Eyenovia by 62.9% during the second quarter. Renaissance Technologies LLC now owns 426,810 shares of the company’s stock worth $1,012,000 after acquiring an additional 164,810 shares during the last quarter. 16.66% of the stock is currently owned by institutional investors.

Eyenovia Company Profile

Eyenovia, Inc, a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system.